Evogene Ltd. (NASDAQ:EVGN) Q3 2023 Earnings Conference Call November 15, 2023 9:00 AM ET

Company Participants

Ofer Haviv - President and Chief Executive Officer

Yaron Eldad - Chief Financial Officer

Amit Noam - Chief Executive Officer of Lavie Bio

Nir Arbel - CPO of Evogene

Conference Call Participants

Ryan Mayer - Lake Street Capital

Brian Wright - ROTH Capital

Benjamin Haynor - Alliance Global Partners

Operator

Ladies and gentlemen, thank you for standing by. Welcome to Evogene's Third Quarter 2023 Results Conference Call. All participants are present in listen-only mode. Following management's formal presentation, instructions will be given for the question-and-answer session. [Operator Instructions] As a reminder, this conference is being recorded November 15, 2023.

Before we begin, I would like to caution that certain statements made during this earnings conference call by Evogene's management will constitute forward-looking statements that relate to future events, risks and uncertainties regarding business strategy, operations and future performance and results of Evogene. I encourage you to review Evogene's filings with the U.S. Securities and Exchange Commission and read the note regarding forward-looking statements in today's earnings release, which states the statements made in the earnings release and, in a similar way, on this earnings conference call that are not historical facts may be deemed forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

For example, Evogene is using forward-looking statements in this call when it discusses the additional orders for Casterra's castor seeds and new collaborations to generate cash flow for the group, Biomica enhancing in preparing for our pre-IND meeting for BMC128 expected tests of LAV312 in fields trials by several multinational companies and Casterra's ability to mitigate production risks and to retain additional seed production subcontractors. All forward-looking statements made herein speak only as of the date of the announcement of results. Many of the factors that impact whether forward-looking statements will come through or beyond the control of Evogene and may cause actual results to differ materially from anticipated results.

Evogene is under no obligation to update publicly or alter our forward-looking statements, whether as a result of new information, future events or otherwise except as otherwise required by law, we expressly disclaim any obligation to do so. More detailed information about the risk factors potentially adversely impacting our performance can be found in our reports filed with the U.S. Securities and Exchange Commission.

Starting the call today is the President and CEO of Evogene, Ofer Haviv, joined by Evogene's CFO, Yaron Eldad.